Biotech Stock Could Turn 4-Year Peak Into Records
BridgeBio Pharma Inc (NASDAQ:BBIO) stock is up 3.3% to trade at $70.36 at last check, and earlier hit a fresh four-year high $70.60 on a bounce off its 20-day moving average.
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript
BridgeBio Pharma, Inc. ( BBIO ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Chinmay Shukla Ananth Sridhar - Chief Operating Officer of Cardiorenal Anna Wade Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma.
BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. ( BBIO ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Chinmay Shukla Neil Kumar - Co-Founder, CEO & Director Matthew Outten - Chief Commercial Officer Thomas Trimarchi - CFO & President Conference Call Participants Salim Syed - Mizuho Securities USA LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Biren Amin - Piper Sandler & Co., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Lin Tsai - Jefferies LLC, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Jason Zemansky - BofA Securities, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Trevor Allred - Oppenheimer & Co. Inc., Research Division Presentation Operator Good afternoon. I will be your conference operator today.
BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock?
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Ananth Sridhar - Chief Operating Officer Chinmay Shukla - VP IR & Strategic Finance Christine Siu - Chief Operating Officer in Residence Justin To - Chief Operating Officer, Skeletal Dysplasias and Gene Therapy Matthew Outten - Chief Commercial Officer Neil Kumar - Co-Founder, CEO & Director Thomas Trimarchi - CFO & President Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Biren N. Amin - Piper Sandler & Co., Research Division Cory William Kasimov - Evercore ISI Institutional Equities, Research Division Gregory Allen Harrison - Scotiabank Global Banking and Markets, Research Division Lin Tsai - Jefferies LLC, Research Division Mani Foroohar - Leerink Partners LLC, Research Division Paul Choi - Goldman Sachs Group, Inc., Research Division Salim Qader Syed - Mizuho Securities USA LLC, Research Division Tyler Martin Van Buren - TD Cowen, Research Division Operator Good afternoon.
BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $1.02 per share a year ago.
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It is time for a move higher in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
BridgeBio: New Data Bolsters The Bull Case
BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from Amvuttra appear overstated, as Attruby script declines were minor and BridgeBio management remains confident in market positioning and pricing. My updated model projects 2025 revenues of $728 million, far above consensus, and sees potential for nearly $1 billion in 2026 from existing patients alone.
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in BridgeBio Pharma (BBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Chinmay Shukla – Vice President-Strategic Finance Neil Kumar – Chief Executive Officer Matt Outten – Chief Commercial Officer Tom Trimarchi – President and Chief Financial Officer Ananth Sridhar – Chief Operating Officer-BridgeBio Cardiorenal Conference Call Participants Salim Syed – Mizuho Tyler Van Buren – TD Cowen Mani Foroohar – Leerink Partners Cory Kasimov – Evercore Greg Harrison – Scotiabank Paul Choi – Goldman Sachs Anupam Rama – JPMorgan Eliana Merle – UBS Jason Zemansky – Bank of America Operator Good afternoon. I will be your conference operator today.
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.05 per share a year ago.
